Advanced Solid Tumors
Why trials studying Advanced Solid Tumors stopped, in this sample of ClinicalTrials.gov.
17 stopped trials with a clear reason; 94% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 15 | 88% |
| futility | 1 | 6% |
| regulatory | 1 | 6% |
Trials
- Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
NCT06719973 · WITHDRAWN · funding business
“Study was terminated due to decision made not to proceed with the clinical trial DDRiver 521, that has not yet commenced enrolment, for strategic reasons.” - A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
NCT05949632 · TERMINATED · funding business
“This was a strategic business decision. There were no safety concerns contributing to this decision.” - Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
NCT06331559 · TERMINATED · funding business
“Company development strategy change” - A Study of ASP2074 in Adults With Solid Tumors
NCT05646797 · TERMINATED · funding business
“Company Strategic Reasons” - A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
NCT05678283 · WITHDRAWN · funding business
“Business Objectives have changed.” - A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
NCT05109975 · TERMINATED · funding business
“This trial was concluded for strategic reasons.” - A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
NCT05083481 · TERMINATED · futility
“Lack of clinical benefit” - Study of INCA 0186 in Subjects With Advanced Solid Tumors
NCT04989387 · TERMINATED · funding business
“This was a strategic business decision. There were no safety concerns contributing to this decision.” - Study of LM-102 in Subjects in Advanced Tumors
NCT04735796 · TERMINATED · funding business
“Business strategy changed” - Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
NCT04747470 · TERMINATED · funding business
“Sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule, GS-3583.” - A Study of EMB-02 in Participants With Advanced Solid Tumors
NCT04618393 · TERMINATED · funding business
“Company's resource optimization and product's development change” - The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
NCT04312282 · TERMINATED · funding business
“The Sponsor has discontinued the development of tesetaxel” - Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
NCT03604783 · TERMINATED · funding business
“Sponsor's decision to terminate further development of the program.” - Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
NCT03739138 · TERMINATED · funding business
“Business Reasons” - TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
NCT03387917 · TERMINATED · funding business
“The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part.” - Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)
NCT03320525 · TERMINATED · regulatory
“Issues with PK detection limits and compliance to protocol at the analytical site.” - A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
NCT03034304 · TERMINATED · funding business
“The study was terminated early due to the COVID-19 pandemic and sponsor's funding constraints, based on promising preliminary safety and efficacy data.”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.